Skip to main content

Featured

UN Security Council Endorses US-Led Gaza Initiative

    US President Donald Trump talks with Israel's Prime Minister Benjamin Netanyahu at the Knesset in Jerusalem The United Nations Security Council has adopted a resolution put forward by the United States in support of President Donald Trump’s plan for Gaza. The measure, which passed after intense negotiations among member states, outlines a framework aimed at stabilizing the region and addressing humanitarian concerns. The resolution emphasizes international cooperation in delivering aid, rebuilding infrastructure, and supporting security arrangements designed to prevent further escalation. While the US hailed the adoption as a diplomatic breakthrough, several council members expressed caution, noting that the plan’s long-term success will depend on the willingness of local stakeholders to engage constructively. Observers say the vote reflects both the urgency of the humanitarian crisis in Gaza and the geopolitical weight of Washington’s involvement. The coming months wil...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment